Oncology CRO
Leveraging decades of oncology and hematology expertise with unmatched precision, our oncology CRO specialists drive the success of your cancer trials.
Strategic Oncology CRO Solutions for Breakthrough Cancer Research
At TFS, we specialize in advancing oncology and hematology clinical research through unparalleled expertise and innovation. With a global network of oncology specialists and a proven track record in designing and executing successful cancer trials, we provide tailored, patient-centered solutions that address the complexities of oncology clinical development. From immuno-oncology and radiopharmaceuticals to precision medicine, our methodologies are designed to support the development of next-generation therapies that transform lives. By combining deep oncology and hematology expertise, operational excellence, and a personalized approach, we empower our partners to navigate regulatory challenges, enhance patient engagement, and achieve clinical trial success.
Ready to advance oncology research? Connect with our oncology clinical trial experts.
Comprehensive Phase I to IV Oncology CRO Services
Backed by Experience and Global Expertise
With nearly 30 years of experience and over 300 oncology and hematology clinical trials completed across all phases, TFS is a trusted partner for advancing cancer research. Our expertise spans solid and hematologic indications, offering end-to-end solutions that ensure every trial is conducted with precision, efficiency, and purpose. TFS provides comprehensive services for oncology trial success, delivering full-service oncology CRO support with specialized solutions that include site activation, patient recruitment, regulatory compliance, and data analysis. By leveraging our global reach and advanced, data-driven methodologies, we ensure efficient, on-time, and on-budget trials that address the most complex clinical development needs.
Global Reach
8,000
+
trial sites across nearly 20 countries
Broad Experience
35
+
indications across a wide spectrum of cancer types
Proven Expertise
300
+
completed oncology clinical trials
Patient Impact
15,000
+
patients enrolled in oncology & hematology clinical studies
Our oncology CRO expertise extends into rare cancer research, providing a specialized and comprehensive foundation for advancing orphan drug development and targeted therapies in these complex and underserved areas.
Decades of Oncology Research Experience and Proven Success
As a leading oncology clinical research organization, TFS brings decades of experience to supporting oncology and hematology clinical research across a wide spectrum of solid tumors and hematologic malignancies. With expertise in managing complex clinical trials and addressing challenges unique to oncology and hematology studies, we ensure high-quality results through operational excellence and scientific precision. Our proven track record in delivering next-generation oncology therapies demonstrates our commitment to advancing transformative cancer treatments and improving patient outcomes.
See how we overcome obstacles to deliver results in oncology research. Read our case study.
Advancing Immunotherapy: TFS Supports a CAR T-Cell Therapy Study in Hematologic Malignancies
Advancing Immunotherapy: TFS Supports a CAR T-Cell Therapy Study in Hematologic Malignancies
Leading Oncology CRO with Innovative Oncology Trial Methodologies
Innovation is integral to TFS’s approach as a trusted oncology CRO partner. Our team employs advanced methodologies such as adaptive trial designs, which provide flexible protocols for early- to late-phase drug development, improving efficiency and decision-making. We also specialize in master protocols, including basket and umbrella trials, to streamline research across solid and hematologic indications. Additionally, our biomarker-driven trials incorporate precision oncology solutions, integrating genomic insights to develop targeted therapies and advance personalized medicine. Through these cutting-edge strategies, TFS supports the development of next-generation, novel oncology therapies while navigating the complexities of oncology clinical research with precision and expertise.
Discover best practices for optimizing oncology trials and improving early-phase study start-up. Read our white paper.
Early-Phase Oncology Study Start-Up in Today’s Clinical Environment
Early-Phase Oncology Study Start-Up in Today’s Clinical Environment
Broad Indication Expertise in Oncology Clinical Studies
TFS offers unparalleled expertise in managing oncology and hematology clinical research, supporting trials across a diverse range of indications with tailored solutions for each therapeutic area. Backed by a robust oncology site network and experienced investigators, we ensure operational efficiency and accelerated enrollment to drive oncology trial success.
Our expertise spans both common and complex indications, demonstrating our commitment to advancing transformative therapies:
Solid Tumors
Breast, prostate, gastrointestinal, cervical, and lung cancers, supported by proven capabilities in oncology clinical research.
Advanced Therapies
CAR-T, cell and gene therapies, and radiopharmaceutical innovations, leveraging our deep experience with next-generation immuno-oncology (IO) therapies.
With our comprehensive capabilities and dedication to precision, TFS is the partner of choice for biotechnology sponsors seeking reliable support in oncology clinical development.
Meet Our Dedicated Oncology CRO Team
Our oncology experts are committed to driving the success of oncology and hematology clinical research. With deep therapeutic knowledge, hands-on leadership, and a track record of excellence in managing complex oncology clinical trials, our team is uniquely positioned to support the development of next-generation, novel oncology therapies. Combining strategic insight with operational expertise, our team ensures your oncology trial achieves its objectives efficiently and effectively. Whether advancing innovative therapies through precision trial methodologies or navigating the complexities of oncology clinical development, our team delivers tailored solutions to ensure the success of your oncology study.
Edyta Korzuch
Executive Director, Project Management, Oncology
Oncology Insights
From Strategy to Patients: Adaptability and Innovation in Trial Design
From Strategy to Patients: Adaptability and Innovation in Trial Design
Insights from ASCO 2025: Oncology Clinical Trial Trends CROs and Sponsors Need to Know
Insights from ASCO 2025: Oncology Clinical Trial Trends CROs and Sponsors Need to Know
Revolutionizing Oncology Trials: The Power of Immunotherapy and Precision Medicine in Cancer Research
Revolutionizing Oncology Trials: The Power of Immunotherapy and Precision Medicine in Cancer Research
Comprehensive Oncology Capabilities: Supporting Every Phase of Clinical Development
TFS provides end-to-end oncology capabilities designed to address the complexities of oncology and hematology clinical research. From early-phase discovery to phase IV studies and real-world evidence (RWE), our comprehensive solutions ensure precise execution and impactful outcomes for oncology trials across all phases.
As a trusted global mid-size oncology CRO, TFS combines flexibility, innovation, and scientific expertise to deliver meaningful results. Whether supporting a single function or providing full-service support, we partner with biotechnology sponsors to advance transformative therapies efficiently and effectively.
Our Hematology-Oncology Portfolio Covers:
- Antibody-Drug Conjugates (ADCs): Specialized expertise in novel, targeted cancer therapies.
- Biologics and Small Molecules: Supporting trials across a wide range of advanced treatments.
- Biomarkers and Companion Diagnostics: Precision tools for oncology clinical research.
- Cell and Gene Therapies: Expertise in next-generation immuno-oncology therapies.
Comprehensive Oncology Trial Design and Management
We collaborate with sponsors to design, optimize, and manage clinical trials. With a global network of trusted investigators and operational excellence, we support trials across solid and hematologic indications, ensuring success through proactive solutions and tailored strategies as part of our end-to-end oncology capabilities.
Learn more 
Phase IV Studies and Real-World Evidence (RWE) Generation
TFS offers support for Phase IV studies and real-world data collection, translating clinical trial findings into actionable insights. These end-to-end oncology capabilities enable therapies to demonstrate value in real-world settings, ensuring they meet patient and stakeholder needs.
Learn more
Strategic Resourcing and FSP Solutions
Our flexible Functional Service Provider (FSP) solutions and Strategic Resourcing options offer customizable support tailored to your trial needs. Whether providing single or multiple contract resources, specific functions, or full-service oncology CRO support, TFS ensures access to top-tier professionals throughout the research lifecycle.
Learn more
Expertise in Complex Study Designs
TFS specializes in complex clinical trials, offering deep expertise in hematologic oncology (hem/onc), novel endpoints, and integrated technologies to meet the demands of innovative cancer therapies. These are a core part of our end-to-end oncology capabilities.
Learn more
Frequently Asked Questions About Our
Oncology & Hematology Clinical Trials
At TFS, we understand that navigating the complexities of oncology clinical trials can be challenging. Whether you’re initiating a Phase I trial or gathering real-world evidence in Phase IV, having a trusted partner is essential. Below, we’ve answered some of the most frequently asked questions about our oncology-focused capabilities to provide clarity and guide you through every step of your clinical trial journey.
What makes TFS a trusted partner for oncology clinical trials?
TFS brings nearly 30 years of specialized experience in oncology and hematology clinical research, having supported over 300 clinical trials across solid and hematologic indications. Our global oncology site network, advanced methodologies, and commitment to delivering on-time and on-budget trials make us a reliable partner for biotechnology sponsors.
How does TFS handle complex oncology clinical trial designs?
Our team excels in managing complex clinical trials with expertise in hematologic oncology (hem/onc), novel endpoints, and integrated technologies. We leverage innovative strategies, such as adaptive trial designs and precision oncology solutions, to ensure efficient and impactful outcomes for oncology trials.
Can TFS support next-generation therapies like CAR-T and gene therapies?
Yes, TFS has extensive experience with next-generation immuno-oncology therapies, including CAR-T, cell and gene therapies, and antibody-drug conjugates (ADCs). Our tailored approaches enable biotechnology sponsors to navigate the complexities of these advanced therapies with confidence.
What makes TFS’s approach to patient recruitment unique?
TFS employs advanced genomic analysis and biomarker assessment to support precision oncology clinical trial recruitment, ensuring the right patients are matched to the right trials. Additionally, our global site network and patient-centered strategies enhance recruitment and retention for trials of all sizes.
Does TFS offer flexible solutions for oncology trials?
Our end-to-end oncology capabilities include Functional Service Provider (FSP) solutions and Strategic Resourcing options, providing customizable support for single functions, contract resources, or full-service oncology CRO support. This flexibility ensures we can meet the specific needs of any trial or sponsor.
How does TFS support post-market and real-world evidence studies?
TFS offers expertise in Phase IV studies and real-world evidence (RWE), translating clinical trial results into actionable insights. These capabilities demonstrate the value of therapies in real-world settings, helping sponsors meet patient and stakeholder needs effectively.
What therapeutic areas within oncology and hematology does TFS specialize in?
Our expertise spans a broad range of cancer indications, including leukemias, lymphomas, solid tumors (e.g., breast, lung, gastrointestinal cancers), and advanced therapies such as cell and gene therapies and biomarker-driven trials.
Where can you find the TFS Oncology Clinical Development team?
TFS regularly attends and presents at leading global oncology conferences and events. You can connect with our team at upcoming meetings such as the American Society of Clinical Oncology (ASCO) Annual Meeting, European Society for Medical Oncology (ESMO) Congress, and Clinical Outsourcing in Oncology Trials (OCT) events. These forums are excellent opportunities to meet our oncology experts, explore partnership opportunities, and learn more about our commitment to advancing cancer research worldwide.
Partner with TFS HealthScience
Ready to advance oncology research? Contact TFS today to explore how we can support your oncology clinical trial needs with precision, expertise, and patient-centered solutions.